世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の原発性硬化性胆管炎治療市場 2018-2022年

Global Primary Sclerosing Cholangitis Treatment Market 2018-2022

IRTNTR23653

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年8月US$2,500
シングルユーザライセンス
110

サマリー

この調査レポートは世界の原発性硬化性胆管炎治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is chronic liver disease that can occur either by itself or due to other diseases. The disease is characterized by the inflammation and thickening of the bile ducts. This obstructs bile flow, which may lead to other liver diseases.
Technavio’s analysts forecast the Global Primary Sclerosing Cholangitis Treatment Market to grow at a CAGR of 3.57% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the primary sclerosing cholangitis treatment market. To calculate the market size, the report considers the revenue generated from the primary sclerosing cholangitis treatment across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, primary sclerosing cholangitis treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Glenmark
- Impax Laboratories
- Mylan
- Teva Pharmaceuticals
Market driver
- Rise in number of liver transplants and UDCA treatment
- For a full, detailed list, view our report

Market challenge
- Poor understanding of PSG pathogenesis
- For a full, detailed list, view our report

Market trend
- Development of affordable PSC drugs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Primary sclerosing cholangitis
MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- UDCA - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Development of affordable PSC drugs
- Surrogate endpoints for clinical trials in PSC
- siRNA therapeutic products for treatment of PSC
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Glenmark
- Impax Laboratories
- Mylan
- TEVA Pharmaceutical
PART 16: APPENDIX
- List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global metabolic disorder therapeutic market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Global - Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Pipeline landscape by development phase
Exhibit 18: Key clinical trials candidates of primary sclerosing cholangitis
Exhibit 19: Product - Market share 2017-2022 (%)
Exhibit 20: Comparison by product
Exhibit 21: UDCA - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: UDCA - Year-over-year growth 2018-2022 (%)
Exhibit 23: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Others - Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Global - Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: ALLERGAN - Overview
Exhibit 45: ALLERGAN - Business segments
Exhibit 46: ALLERGAN - Organizational developments
Exhibit 47: ALLERGAN - Geographic focus
Exhibit 48: ALLERGAN - Segment focus
Exhibit 49: ALLERGAN - Key offerings
Exhibit 50: ALLERGAN - Key customers
Exhibit 51: Glenmark - Overview
Exhibit 52: Glenmark - Business segments
Exhibit 53: Glenmark? Organizational developments
Exhibit 54: Glenmark - Geographic focus
Exhibit 55: Glenmark - Segment focus
Exhibit 56: Glenmark - Key offerings
Exhibit 57: Glenmark - Key customers
Exhibit 58: Impax Laboratories - Overview
Exhibit 59: Impax Laboratories - Business segments
Exhibit 60: Impax Laboratories - Organizational developments
Exhibit 61: Impax Laboratories - Geographic focus
Exhibit 62: Impax Laboratories - Segment focus
Exhibit 63: Impax Laboratories - Key offerings
Exhibit 64: Impax Laboratories - Key customers
Exhibit 65: Mylan - Overview
Exhibit 66: Mylan - Business segments
Exhibit 67: Mylan - Organizational developments
Exhibit 68: Mylan - Geographic focus
Exhibit 69: Mylan - Segment focus
Exhibit 70: Mylan - Key offerings
Exhibit 71: Mylan - Key customers
Exhibit 72: TEVA Pharmaceutical - Overview
Exhibit 73: TEVA Pharmaceutical - Business segments
Exhibit 74: TEVA Pharmaceutical - Organizational developments
Exhibit 75: TEVA Pharmaceutical - Geographic focus
Exhibit 76: TEVA Pharmaceutical - Segment focus
Exhibit 77: TEVA Pharmaceutical - Key offerings
Exhibit 78: TEVA Pharmaceutical - Key customers
-

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る